FDA Rejects Sotagliflozin As Insulin Add-On | Docwire News
The FDA rejected a new drug application for sotagliflozin (Zynquista) for use as an add-on to insulin therapy for glycemic control in adults with type 1 diabetes and CKD.
The FDA rejected a new drug application for sotagliflozin (Zynquista) for use as an add-on to insulin therapy for glycemic control in adults with type 1 diabetes and CKD.
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
Amivantamab plus lazertinib showed a clinical benefit rate of 58% in a population of certain patients with non-small cell lung cancer (NSCLC) who have limited…
What you need to buy to make sure your new year resolution of following a plant-based diet lasts beyond January
A randomized trial of 156 people in Pakistan found a plant-based diet significantly improved LDL “bad” cholesterol, HbA1c, fasting blood glucose, c-reactive protein (a marker…
What are we to make of this? The National Academies of Sciences, Engineering, and Medicine’s Review of Evidence on Alcohol and Health says moderate drinking…
Looking for one simple thing to add to your life in 2025 and improve your health? Look no further than drinking a glass of water,…
Veganuary promotes a 31-day vegan challenge to raise awareness of a vegan lifestyle and its health benefits, globally.
When comparing vegan, vegetarian, and omnivore diet types, researchers found that food quality and diversity may have the biggest impact on the health and structure…
A new model called the Florey Dementia Index (FDI) can accurately predict the age at onset of MCI and AD.
A European review of health studies shows that plant-based meat is healthy, despite its association with ultra-processed foods.